A clinical trial of MK-507, Trusopt, for raised intraocular pressure - The Australian experience

Australian and New Zealand Journal of Ophthalmology

Volumn 24, Issue 2, 1996, Pages 111-115

  Gillies, W E ^a,b   Brooks, Anne M V ^a  

^a ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^b NONE   (Australia)

Author keywords

glaucoma treatment; MK 507; topical carbonic anhydrase inhibitor

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; TIMOLOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; MALE; TOPICAL DRUG ADMINISTRATION;

EID: 0029763469     PISSN: 08149763     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-9071.1996.tb01563.x     Document Type: Article

References (23)

1. Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox. Am J Ophthalmol 1954;37:13-15.
2. Grant WM, Trotter RR. Diamox (acetazoleamide) in treatment of glaucoma. Arch Ophthalmol 1954;51:735-9.
3. Becker B. The mechanism of the fall in intraocular pressure induced by the carbonic anhydrase inhibitor, diamox. Am J Ophthalmol 1955;39(Feb Pt II):177-82.
4. Becker B. Carbonic anhydrase and the formation of aqueous humor: The Friedenwald Memorial Lecture. Am J Ophthalmol 1959;47(Jan Pt 11):342-61.
5. Becker B, Middleton WH. Long-term acetazoleamide (diamox) administration in therapy of glaucomas. Arch Ophthalmol 1955; 54: 187-92.
6. Grant WM, Schuman JS. Acetazolamide. In: Toxicology of the eye. 4th ed. Springfield, Ill: Charles C Thomas, 1993;43-52.
7. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects: Serum chemical analysis. Arch Ophthalmol 1977;95:1378-82.
8. Mogk LG, Cyrlin MN. Blood dyscrasias and carbonic anhydrase inhibitors. Ophthalmology 1988;95:768-71.
9. Lichter PR. Carbonic anhydrase inhibitors, blood dyscrasias, and standard-of-care. [Editorial] Ophthalmology 1988;95:711-12.
10. Keisu M, Wiholm B-E, Öst Å, Mortimer Ö. Acetazolamide-associated aplastic anaemia. J Intern Med 1990;228:627-32.
11. Moroi-Fetters SE, Metz EN, Chambers RB, Davidorf FH. Aplastic anemia with platelet autoantibodies in a patient after taking methazolamide. Am J Ophthalmol 1990;110:570-1.
12. Fraunfelder FT, Fraunfelder FW. Short-term use of carbonic anhydrase inhibitors and hematologic side effects. Arch Ophthalmol 1992;110:446-7.
13. Shapiro S, Fraunfelder FT. Acetazolamide and aplastic anemia. Am J Ophthalmol 1992;113:328-30.
14. Bron AM, Lippa EA, Hofmann HM, Feicht BI, Royer JG, Brunner-Ferber FL, et al. MK-927: A topically effective carbonic anhydrase inhibitor in patients. Arch Ophthalmol 1989;107:1143-6.
15. Higginbotham EJ, Kass MA, Lippa EA, Batenhorst RL, Panebianco DL, Wilensky JT. MK-927: a topical carbonic anhydrase inhibitor: dose-response and duration of action. Arch Ophthalmol 1990;108:65-8.
16. Pfeiffer N, Hennekes R, Lippa EA, Grehn F, Garus H, Brunner-Ferber FL. A single dose of the topical anhydrase inhibitor MK-927 decreases IOP in patients. Br J Ophthalmol 1990;74:405-8.
17. Lippa EA, Carson L-E, Ehinger B, Eriksson L-O, Finnström K, Holmin C, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992;110:495-9.
18. Wilkerson M, Cyrlin M, Lippa EA, Esposito D, Deasy D, Panebianco D, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical anhydrase inhibitor. Arch Ophthalmol 1993;11:1343-50.
19. Kitazawa Y, Azuma I, Iwata K, Tsukahara S, Shiose Y, Araie M, et al. Dorzolamide, a topical carbonic anhydrase inhibitor: a two-week dose-response study in patients with glaucoma or ocular hypertension. J Glaucoma 1994;3:275-9.
20. Strahlman E, Tipping R, Vogel R, the international dorzolamide study group. A double-masked, randomized 1-year study comparing dorzolamide (trusopt), timolol and betaxolol. Arch Ophthalmol 1995;113:1009-16
21. Brooks AMV, Gillies WE, West RH. Betaxolol eye drops as a safe medication to lower intraocular pressure. Aust NZ J Ophthalmol 1987;15:125-9.
22. Brooks AMV, Burdon JGW, Gillies WE. The significance of reactions to betaxolol reported by patients. Aust NZ J Ophthalmol 1989;17:353-5.
23. Grant WM, Schuman JS. Beta-adrenergic blocking agents. In: Toxicology of the eye. 4th ed. Springfield, Ill: Charles C Thomas, 1993;221-62.